<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248037</url>
  </required_header>
  <id_info>
    <org_study_id>2017-003</org_study_id>
    <nct_id>NCT03248037</nct_id>
  </id_info>
  <brief_title>Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation</brief_title>
  <official_title>Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cornea Research Foundation of America</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cornea Research Foundation of America</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cornea transplant recipients who are using topical corticosteroids long-term to prevent
      transplant rejection will be randomized to use netarsudil or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>from date of randomization until the date of first documented intraocular pressure elevation up to 9 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Fuchs' Endothelial Dystrophy</condition>
  <condition>Bullous Keratopathy</condition>
  <arm_group>
    <arm_group_label>Netarsudil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo eye drop, dosed topically once a day for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil</intervention_name>
    <description>netarsudil opthalmic solution 0.02%</description>
    <arm_group_label>Netarsudil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo eye drops</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age; male or female patient undergoing Descemet membrane
             endothelial keratoplasty; patient is able and willing to administer eye drops; patient
             is able to comprehend and has signed the Informed Consent form; patient is likely to
             complete the nine-month course of the study.

        Exclusion Criteria:

          -  A patient exhibiting pre-operative intraocular inflammation; a patient with a known
             sensitivity to any of the ingredients in the study medications; a patient who has a
             condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the
             investigator's opinion may put the patient at significant risk, may confound the study
             results, or may interfere significantly with the patient's participation in the study;
             a patient with abnormal eyelid function; a patient that is exhibiting active corneal
             ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis;
             a patient who has been diagnosed with uncontrolled glaucoma, prior aqueous shunt or
             trabeculectomy, or with preoperative IOP &gt; 22 mm Hg in the potential study eye;
             presence of any ocular disease that would interfere with the evaluation of the study
             treatment (however, patients with a history of cystoid macular edema, age-related
             macular degeneration, corneal neovascularization, and other non-interfering
             comorbidities may be enrolled); a patient with a history of non-compliance with using
             prescribed medication; a patient who is concurrently involved in or participated in
             another randomized clinical trial within 30 days prior to enrollment in this study;
             patients who are pregnant or planning to become pregnant within the duration of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne O Price, PhD</last_name>
    <phone>317-814-2990</phone>
    <email>mprice@cornea.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Price, PhD</last_name>
      <phone>317-814-2990</phone>
      <email>mprice@cornea.org</email>
    </contact>
    <investigator>
      <last_name>Francis W Price, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew T Feng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fini ME, Schwartz SG, Gao X, Jeong S, Patel N, Itakura T, Price MO, Price FW Jr., Varma R, Stamer WD. Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res. 2017 Jan;56:58-83. doi: 10.1016/j.preteyeres.2016.09.003. Epub 2016 Sep 22. Review.</citation>
    <PMID>27666015</PMID>
  </reference>
  <reference>
    <citation>Vajaranant TS, Price MO, Price FW, Gao W, Wilensky JT, Edward DP. Visual acuity and intraocular pressure after Descemet's stripping endothelial keratoplasty in eyes with and without preexisting glaucoma. Ophthalmology. 2009 Sep;116(9):1644-50. doi: 10.1016/j.ophtha.2009.05.034. Epub 2009 Jul 29.</citation>
    <PMID>19643499</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

